DISSEMINATED TUBERCULOSIS PRESENTING AS HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Abstract
ABSTRACT
Hemophagocytic lymphohistiocytosis (HLH) is an immune dysregulation syndrome which is characterized by widespread but ineffective activation
of immune system of our body. This activation leads to release of a large pool of cytokines from the activated lymphocytes and macrophages. This
hypercytokinemia leads to the development of characteristic features of HLH such as fever, cytopenias, hepatosplenomegaly, raised serum ferritin
level, hemophagocytosis in marrow/spleen/lymph nodes, low fibrinogen and or hypertriglyceridemia, low natural killer cell activity, and high-soluble
CD25 [1]. Five out of the above eight features are required for the diagnosis. There are 2 variants of HLH, primary HLH; where the defect in the
immune system is hereditary and secondary HLH; where it is caused by other secondary diseases such as infections, hematological malignancies,
autoimmune and auto-inflammatory diseases. In this article, we have reported a case of HLH, which was secondary to disseminated tuberculosis.
There are only few case reports of HLH secondary to disseminated tuberculosis. Mortality may be as high as 50%. Although tuberculosis has various
manifestations, our patient presented with fever, skin rash, cytopenias, splenomegaly, and very high ferritin. Marrow examination showed epithelioid
granuloma, hemophagocytosis, and positive Ziehl–Neelsen staining. At present, no definite treatment guidelines have been formulated because
of multiple drug interactions and toxicities. We treated our patient with non-hepatotoxic anti-tubercular drugs and steroids, followed by addition
of isoniazid, rifampicin, and pyrazinamide on improvement of hepatic profile. Thus, high index of clinical suspicion, prompt diagnosis, and early
management may reduce the mortality in this devastating disease. Moreover, this is more common in immunocompromised patients, but here, we
have diagnosed this case in an immunocompetent man.
Keywords: Erythematous rash, Fever, Disseminated tuberculosis.
Downloads
References
REFERENCES
Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis:
Pathogenesis and treatment. Hematology Am Soc Hematol Educ
Program 2013;2013(1):605-11.
Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis.
Arch Dis Child 1952;27(136):519-25.
Weitzman S. Approach to hemophagocytic syndromes. Hematology
Am Soc Hematol Educ Program 2011;2011:178-83.
Asian J Pharm Clin Res, Vol 9, Issue 3, 2016, 5-7
Kargupta et al.
Filipovich AH. The expanding spectrum of hemophagocytic
lymphohistiocytosis. Curr Opin Allergy Clin Immunol 2011;11(6):512-6.
Bode SF, Lehmberg K, Maul-Pavicic A, Vraetz T, Janka G, Stadt UZ,
et al. Recent advances in the diagnosis and treatment of hemophagocytic
lymphohistiocytosis. Arthritis Res Ther 2012;14(3):213.
Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis.
Annu Rev Med 2012;63:233-46.
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH,
Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines
for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer
;48(2):124-31.
Claessens YE, Pene F, Tulliez M, Cariou A, Chiche JD. Life-threatening
hemophagocytic syndrome related to mycobacterium tuberculosis. Eur
J Emerg Med 2006;13(3):172-4.
Rathnayake PV, Kularathne WK, De Silva GC, Athauda BM,
Nanayakkara SN, Siribaddana A, et al. Disseminated tuberculosis
presenting as hemophagocytic lymphohistiocytosis in an
immunocompetent adult patient: A case report. J Med Case Rep
;9:294.
Park HS, Kim DY, Lee JH, Lee JH, Kim SD, Park YH, et al.
Clinical features of adult patients with secondary hemophagocytic
lymphohistiocytosis from causes other than lymphoma: An
analysis of treatment outcome and prognostic factors. Ann Hematol
;91(6):897-904.
Balkis MM, Bazzi L, Taher A, Salem Z, Uthman I, Kanj N, et al. Severe
hemophagocytic syndrome developing after treatment initiation for
disseminated Mycobacterium tuberculosis: Case report and literature
review. Scand J Infect Dis 2009;41(6-7):
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.